← Back to Search
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium (MarkVCID Trial)
Saint Louis, MO
N/A
Waitlist Available
Led By Steven M. Greenberg, MD, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the cognitive battery is implemented, and global cognition calculated, at baseline and years 1, 2 and 3 post-baseline.
Awards & highlights
No Placebo-Only Group
Summary
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function.
Eligible Conditions
- Dementia
- Cognitive Impairment
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ the cognitive battery is implemented, and global cognition calculated, at baseline and years 1, 2 and 3 post-baseline.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the cognitive battery is implemented, and global cognition calculated, at baseline and years 1, 2 and 3 post-baseline.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
SVD progression as measured by decline in global cognition
Secondary study objectives
SVD progression as measured by decline in executive function
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Subjective Cognitive Decline (SCD)Experimental Treatment1 Intervention
Subjective cognitive decline is defined as:
1. Cognitive concerns based on a Short eCog-12 score ≥ 3 (based on administration to participant), AND
2. Normal cognition (neuropsychological testing within normal range).
Group II: Normal Cognition (NC) with at least 1 vascular risk factorExperimental Treatment1 Intervention
NC is defined as:
1. No diagnosis of SCD, MCI, or dementia; AND
2. CDR: Sum of Boxes = 0 AND neuropsychological testing in normal range.
Participants must have at least 1 of the following criteria prior to enrollment:
Diabetes (at least 1):
* Fasting (8-hour) blood sugar ≥126 mg/dL
* Random or Post-prandial blood sugar ≥200 mg/dL
* HbA1C ≥6.5%
* Treatment with anti-diabetic medicine
Hypertension plus (at least 2):
* Use of anti-hypertensive medications for lowering blood pressure for ≥10 years
* Current use of 2 or more anti-hypertensive meds for lowering blood pressure
* Blood pressure in a research or clinical setting in the last 2 years with SBP ≥140 or DBP ≥90
* Second blood pressure reading in a research or clinical setting in the last 2 years (different date) with SBP ≥140 or DBP ≥90
* Evidence of likely HTN end organ damage
MRI factors (at least 1):
* Peri-Ventricular Fazekas Extent Grade or Deep Fazekas Extent Grade ≥2
* ≥1 microbleeds
* ≥1 lacunar infarcts
Group III: Mild DementiaExperimental Treatment1 Intervention
Mild dementia is defined as:
1. The subject has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria:
1. Interfere with ability to function as before at work or at usual activities?
2. Represent a decline from previous levels of functioning?
3. Are not explained by delirium or major psychiatric disorder? AND
2. Impairment in one\* or more of the following domains.
1. Impaired ability to acquire and remember new information.
2. Impaired reasoning and handling of complex tasks, poor judgment.
3. Impaired visuospatial abilities.
4. Impaired language functions.
5. Changes in personality, behavior, or comportment \* In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, posterior cortical atrophy), the subject must not fulfill criteria for MCI.
AND
3. CDR: Global Score = 0.5 or 1
Group IV: Mild Cognitive Impairment (MCI)Experimental Treatment1 Intervention
Mild cognitive impairment is defined as:
1. There is a cognitive concern, i.e., the subject, the co-participant, or a clinician is concerned about a change in cognition compared to the subject's previous level.
2. There is impairment in one or more cognitive domains (memory, language, executive function, attention, and visuospatial skills) that is greater than would be expected for the patient's age and educational background.
3. There is largely preserved independence in functional abilities (no change from prior level of functioning or requires only extra effort and minimal aids or assistance).
4. There is no evidence of dementia (cognitive changes are mild and there is no evidence of a significant impairment in social or occupational functioning).
Find a Location
Closest Location:Washington University in St. Louis· Saint Louis, MO
Who is running the clinical trial?
University of California, Los AngelesOTHER
1,591 Previous Clinical Trials
10,423,867 Total Patients Enrolled
15 Trials studying Dementia
7,897 Patients Enrolled for Dementia
Olive View-UCLA Education & Research InstituteOTHER
33 Previous Clinical Trials
878,121 Total Patients Enrolled
1 Trials studying Dementia
144 Patients Enrolled for Dementia
Johns Hopkins UniversityOTHER
2,362 Previous Clinical Trials
15,160,322 Total Patients Enrolled
33 Trials studying Dementia
80,170 Patients Enrolled for Dementia
University of KentuckyOTHER
197 Previous Clinical Trials
222,463 Total Patients Enrolled
Duke UniversityOTHER
2,494 Previous Clinical Trials
5,910,532 Total Patients Enrolled
21 Trials studying Dementia
39,128 Patients Enrolled for Dementia
University of New MexicoOTHER
392 Previous Clinical Trials
3,524,559 Total Patients Enrolled
1 Trials studying Dementia
575 Patients Enrolled for Dementia
Washington University School of MedicineOTHER
2,022 Previous Clinical Trials
2,350,352 Total Patients Enrolled
20 Trials studying Dementia
7,027 Patients Enrolled for Dementia
Massachusetts General HospitalLead Sponsor
3,061 Previous Clinical Trials
13,423,889 Total Patients Enrolled
26 Trials studying Dementia
200,831 Patients Enrolled for Dementia
Mayo ClinicOTHER
3,414 Previous Clinical Trials
3,207,297 Total Patients Enrolled
26 Trials studying Dementia
15,103 Patients Enrolled for Dementia
University of Southern CaliforniaOTHER
954 Previous Clinical Trials
1,607,106 Total Patients Enrolled
14 Trials studying Dementia
250,986 Patients Enrolled for Dementia